[非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药机制的研究进展]
[Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
作者信息
Li Yuan, Song Lihua
机构信息
Department of Internal Medicine, Shandong Tumor Hospital, Shandong Academy of Medical Sciences Jinan 250117, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2012 Feb;15(2):106-11. doi: 10.3779/j.issn.1009-3419.2012.02.08.
Abstract
With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. However, the efficacy of EGFR-TKIs is limited by either primary (de novo) or acquired resistance after therapy. This review will focus on recently identified mechanisms of primary and acquired resistance to EGFR TKIs and strategies currently being employed to overcome resistance.
摘要
随着对肿瘤生物学的深入了解，阻断癌症进展途径的新型分子靶向策略已被评估为治疗非小细胞肺癌（NSCLC）的一种新的治疗方法。表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs），如吉非替尼和厄洛替尼，在部分非小细胞肺癌患者群体中对EGFR突变型肺癌显示出良好的反应。然而，EGFR-TKIs的疗效受到治疗后原发性（从头）或获得性耐药的限制。本综述将聚焦于最近发现的对EGFR-TKIs原发性和获得性耐药的机制以及目前用于克服耐药的策略。
相似文献
1
[Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].[非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药机制的研究进展]
Zhongguo Fei Ai Za Zhi. 2012 Feb;15(2):106-11. doi: 10.3779/j.issn.1009-3419.2012.02.08.
2
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的临床定义。
J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.
3
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）治疗携带 TKI 敏感型 EGFR 突变的非小细胞肺癌患者的原发耐药：一项探索性研究。
Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.
4
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.EGFR 酪氨酸激酶抑制剂吉非替尼/厄洛替尼和 ALK 抑制剂克唑替尼耐药的机制。
Lung Cancer. 2013 Sep;81(3):328-336. doi: 10.1016/j.lungcan.2013.05.020. Epub 2013 Jun 25.
5
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌：系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.
6
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂的耐药机制及新一代药物的研发
J Biomed Biotechnol. 2011;2011:165214. doi: 10.1155/2011/165214. Epub 2011 Jun 2.
7
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).表皮生长因子受体（EGFR）突变在一系列非小细胞肺癌（NSCLC）患者中的存在情况，以及对 EGFR 特异性酪氨酸激酶抑制剂（TKIs）的反应率。
Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.
8
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
9
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.非小细胞肺癌中表皮生长因子受体（EGFR）的激活和耐药性突变：在EGFR酪氨酸激酶抑制剂临床反应中的作用
Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198.
10
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体：RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
引用本文的文献
1
Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report.克唑替尼治疗非小细胞肺癌患者的分子病理预测诊断：一例报告
Oncol Lett. 2017 Dec;14(6):7545-7548. doi: 10.3892/ol.2017.7167. Epub 2017 Oct 11.
2
[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy
in Non-small Cell Lung Cancer Patients in Shandong].[山东非小细胞肺癌患者分子靶向治疗的基因表达与临床特征]
Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):14-20. doi: 10.3779/j.issn.1009-3419.2017.01.02.
本文引用的文献
1
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.克服肺癌表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的新策略。
Clin Cancer Res. 2011 Sep 1;17(17):5530-7. doi: 10.1158/1078-0432.CCR-10-2571. Epub 2011 Jul 20.
2
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.BCRP/ABCG2 表达水平升高使野生型 EGFR 表达细胞获得对吉非替尼的耐药性。
PLoS One. 2011;6(6):e21428. doi: 10.1371/journal.pone.0021428. Epub 2011 Jun 23.
3
Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.晚期非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂耐药的机制：临床和分子方面的考虑。
Curr Med Chem. 2011;18(11):1613-28. doi: 10.2174/092986711795471383.
4
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.比较原发性非小细胞肺癌和局部淋巴结转移之间 KRAS 和 EGFR 基因状态：对临床实践的影响。
J Exp Clin Cancer Res. 2011 Mar 17;30(1):30. doi: 10.1186/1756-9966-30-30.
5
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.通过去抑制 FGFR2 和 FGFR3 表达，非小细胞肺癌细胞系中快速获得对 EGFR 酪氨酸激酶抑制剂的耐药性。
PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.
6
Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.非小细胞肺癌中 Kras 基因突变和拷贝数增益的评估。
J Thorac Oncol. 2011 Jan;6(1):15-20. doi: 10.1097/JTO.0b013e31820594f0.
7
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.TGF-β/IL-6 轴介导肺癌对分子靶向治疗的选择性和适应性耐药机制。
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. doi: 10.1073/pnas.1009472107. Epub 2010 Aug 16.
8
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.非小细胞肺癌中的 MET 激活与 EGFR 抑制剂的获得性耐药以及脑转移的发生有关。
Am J Pathol. 2010 Jul;177(1):415-23. doi: 10.2353/ajpath.2010.090863. Epub 2010 May 20.
9
Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.获得性西妥昔单抗耐药是由 PTEN 不稳定性增加介导的，并导致 HCC827 NSCLC 细胞对吉非替尼产生交叉耐药。
Cancer Lett. 2010 Oct 28;296(2):150-9. doi: 10.1016/j.canlet.2010.04.006. Epub 2010 May 4.
10
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.磷酸酶和张力蛋白同源物通过靶向 EGFR 进行降解来调节表皮生长因子受体 (EGFR) 抑制剂的反应。
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6459-64. doi: 10.1073/pnas.0911188107. Epub 2010 Mar 22.
Zotero 插件